Latest News & Updates of Loncom Pharma

On April 15, 2022, the National Drug Administration approves the production and listing of Lacosamide Oral Solution (National Drug Approval Number H20223222), which lets Shandong Loncom Pharmaceutical Co.,Ltd. be the first successful imitation enterprise on this product in China.Lacosamide Oral Solu

In order to learn, promote, and implement GMP and regulations better, stimulate employees' enthusiasm for learning, enhance their quality awareness, and improve the quality management level of the enterprise, the Quality Management Department organizes the "2022 GMP and Regulatory Knowledge Competit

Recently, API, Lacosamide, obtains CEP certificate (No. R0-CEP 2021-451-Rv 00) approved and issued by European Directorate for the Quality of Medicines & Health Care (EDQM). It signifies the high recognition of the production quality system and R&D capabilities of Shandong Loncom Pharmaceutical Co.,